{"entity":{"id":"nct06353386","kind":"trial","name":"Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)","aka":[],"tldr":"A phase 1/2 trial of Opevesostat, Olaparib, Docetaxel, Cabazitaxel, Dexamethasone and Prednisone in prostate cancer, run by Merck Sharp & Dohme LLC, now recruiting.","summary":"Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) is a phase 1/2 interventional study registered as NCT06353386 by Merck Sharp & Dohme LLC, with 220 participants planned, started 2024-05-20 and due to reach its primary completion in 2029-01-15. Interventions recorded: Opevesostat, Olaparib, Docetaxel, Cabazitaxel, Fludrocortisone acetate and Dexamethasone.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06353386","url":"https://clinicaltrials.gov/study/NCT06353386"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate","prostate-mcrpc"],"sections":[],"technologies":[],"targets":[],"drugs":["opevesostat","olaparib","docetaxel","cabazitaxel","dexamethasone","prednisone"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06353386","phase":"1/2","setting":"MK-5684-01A Substudy: A Phase 1/2 Umbrella Substudy of MK-5684-U01 Master Protocol to Evaluate the Safety and Efficacy of MK-5684-based Treatment Combinations or MK-5684 Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)","sponsor":"Merck Sharp & Dohme LLC","participation":[{"nct":"NCT06353386","source":"https://clinicaltrials.gov/study/NCT06353386","fetchedAt":"2026-10-07T16:54:34.595Z","studySha256":"f26d58acf5a6917823df87133028b61368bf92d887988910a6fa9df8c8e233c2","overallStatus":"RECRUITING","lastUpdatePosted":"2026-10-06","leadSponsor":"Merck Sharp & Dohme LLC","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":220,"enrolmentType":"ESTIMATED","siteCount":77,"recruitingSiteCount":68,"countries":["Australia","Canada","Chile","Colombia","Denmark","Finland","France","Germany","Ireland","Israel","Italy","Japan","New Zealand","Poland","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2024-05-20","startedType":"actual","enrolled":220,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06353386/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"cabazitaxel","kind":"drug","name":"Cabazitaxel","route":"/drugs/cabazitaxel/"},{"id":"dexamethasone","kind":"drug","name":"Dexamethasone","route":"/drugs/dexamethasone/"},{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"},{"id":"opevesostat","kind":"drug","name":"Opevesostat","route":"/drugs/opevesostat/"},{"id":"prednisone","kind":"drug","name":"Prednisone","route":"/drugs/prednisone/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}